Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter net income of $1.08 billion. On a per-share basis, the Boston-based company said it had profit of $4.20.

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.

In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The ...

I've been writing, editing and optimizing search content for 10 years. Yes, sleeper sofas are still a thing—and they’re not built like the creaky, lumpy pull-out contraption in your memory. As home ...